The stock of Syneos Health Inc. (NASDAQ:SYNH) last traded at $41.52, down -0.05% from the previous session.
SYNH stock price is now 10.24% away from the 50-day moving average and -3.09% away from the 200-day moving average. The market capitalization of the company currently stands at $4.31B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
With the price target reduced from $30 to $28, JP Morgan Downgraded its rating from Neutral to Underweight for Syneos Health Inc. (NASDAQ: SYNH). On January 17, 2023, Barclays Downgraded its previous ‘Overweight’ rating to ‘Underweight’ on the stock reducing its target price from $30 to quote $25, while ‘Mizuho’ rates the stock as ‘Neutral’.
In other news, Brooks Michael Lee, Chief Operating Officer sold 1,002 shares of the company’s stock on Jul 28. The stock was sold for $78,156 at an average price of $78.00. Upon completion of the transaction, the Chief Operating Officer now directly owns 47,552 shares in the company, valued at $1.97 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 28, Chief Operating Officer Brooks Michael Lee sold 500 shares of the business’s stock. A total of $39,000 was realized by selling the stock at an average price of $78.00. This leaves the insider owning 9,342 shares of the company worth $0.39 million. Insiders disposed of 55,389 shares of company stock worth roughly $2.3 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SYNH stock. A new stake in Syneos Health Inc. shares was purchased by SESSA CAPITAL IM, L.P. during the first quarter worth $37,891,000. POINT72 ASSET MANAGEMENT, L.P. invested $29,656,000 in shares of SYNH during the first quarter. In the first quarter, FARALLON CAPITAL MANAGEMENT LLC acquired a new stake in Syneos Health Inc. valued at approximately $19,597,000. HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND acquired a new stake in SYNH for approximately $17,664,000. RENAISSANCE TECHNOLOGIES LLC purchased a new stake in SYNH valued at around $12,028,000 in the second quarter. In total, there are 453 active investors with 99.30% ownership of the company’s stock.
With an opening price of $41.58 on Thursday morning, Syneos Health Inc. (NASDAQ: SYNH) set off the trading day. During the past 12 months, Syneos Health Inc. has had a low of $22.89 and a high of $79.77. As of last week, the company has a debt-to-equity ratio of 0.77, a current ratio of 1.20, and a quick ratio of 1.20. According to the stock market information, the enterprise value for the company is $7.09B, which is based on a 28.89 price-to-earnings ratio, a 27.00 price-to-earnings-growth ratio, and a beta of 1.61. The fifty day moving average price for SYNH is $37.71 and a two-hundred day moving average price translates $42.73 for the stock.
The latest earnings results from Syneos Health Inc. (NASDAQ: SYNH) was released for Mar, 2023. According to the Diagnostics & Research Company, earnings per share came in at $0.75, beating analysts’ expectations of $0.66 by 0.09. This compares to $0.44 EPS in the same period last year. The net profit margin was 2.70% and return on equity was 4.30% for SYNH. The company reported revenue of $1.36 billion for the quarter, compared to $1.34 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.54 percent. For the current quarter, analysts expect SYNH to generate $1.26B in revenue.
Syneos Health Inc.(SYNH) Company Profile
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
